INBX · Inhibrx Biosciences, Inc.
$99.15
-2.33 (-2.30%)
At close · Aug 20
Market Cap
$1.49B
Shares
14.72M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$99.15
Open$98.65
Day$96.57–102.50
52W close$24.16–141.84
Avg vol 30d241K
Short int3.3M · 22.7% float · 15.6d
Short vol77%
Last earningsMay 11, 2026
DataMay 2024–Aug 2026
Filing10-Q · Aug 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+14%
above
Price vs 50-day avg
+9%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
64%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+17%
trailing
6-month return
+34%
trailing
YTD return
+26%
this year
Relative strength
+23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $91 › 200d $87 — 50d above 200d
Institutional flow
Accumulating
+20% holders QoQ · +50 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
22.70% of float · ▼ -2.7% MoM · 15.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
165 holders — near 2-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
+550%
Y/Y
EPS growth
−108%
Y/Y
Free cash flow
$-129.8M
Balance sheet
$23.7M
net cash
Quant / Vol
risk profile
Volatility
129%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+14%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
64%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $91 › 200d $87 — 50d above 200d
Institutional flow
Accumulating
+20% holders QoQ · +50 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
22.70% of float · ▼ -2.7% MoM · 15.6 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
165 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $24
Now $99 · 64%
Range high $142
vs 200-day avg +14%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INBX
this stock
Inhibrx Biosciences, Inc.
|
$1.49B | +25.5% | +550.0% | — | 22.7% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INBX | +2.2% | +16.7% | +33.8% | +20.8% | +25.5% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +4.2% | +13.3% | +22.6% | +18.8% | +13.7% |